

# World Journal of *Stem Cells*

*World J Stem Cells* 2019 July 26; 11(7): 375-444



**EDITORIAL**

- 375** Predicting differentiation potential of human pluripotent stem cells: Possibilities and challenges  
*Liu LP, Zheng YW*

**REVIEW**

- 383** Presence and role of stem cells in ovarian cancer  
*Kenda Suster N, Virant-Klun I*
- 398** Targeting cancer stem cells in drug discovery: Current state and future perspectives  
*Du FY, Zhou QF, Sun WJ, Chen GL*

**MINIREVIEWS**

- 421** Induced pluripotent stem cells, a giant leap for mankind therapeutic applications  
*Bragança J, Lopes JA, Mendes-Silva L, Almeida Santos JM*
- 431** Using transcription factors for direct reprogramming of neurons *in vitro*  
*Wazan LE, Urrutia-Cabrera D, Wong RCB*

**ABOUT COVER**

Editorial Board Member of *World Journal of Stem Cells*, Y Murat Elçin, PhD, Full Professor, Ankara University Faculty of Science, ElcinLab, Founder and CEO, Biovalda Health Technologies, Inc., Ankara 06100, Turkey

**AIMS AND SCOPE**

*World Journal of Stem Cells* (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

The *WJSC* covers topics concerning all aspects of stem cells: embryonic, neural, hematopoietic, mesenchymal, tissue-specific, and cancer stem cells; the stem cell niche, stem cell genomics and proteomics, etc.

We encourage authors to submit their manuscripts to *WJSC*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

**INDEXING/ABSTRACTING**

The *WJSC* is now indexed in PubMed, PubMed Central, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Biological Abstracts, and BIOSIS Previews. The 2019 Edition of Journal Citation Reports cites the 2018 impact factor for *WJSC* as 3.534 (5-year impact factor: N/A), ranking *WJSC* as 16 among 26 journals in Cell and Tissue Engineering (quartile in category Q3), and 94 among 193 journals in Cell Biology (quartile in category Q2).

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Responsible Electronic Editor: *Yu-Jie Ma*

Proofing Production Department Director: *Yun-Xiaojuan Wu*

**NAME OF JOURNAL**

*World Journal of Stem Cells*

**ISSN**

ISSN 1948-0210 (online)

**LAUNCH DATE**

December 31, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Tong Cao, Shengwen Calvin Li, Carlo Ventura

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-0210/editorialboard.htm>

**EDITORIAL OFFICE**

Jin-Lei Wang, Director

**PUBLICATION DATE**

July 26, 2019

**COPYRIGHT**

© 2019 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Using transcription factors for direct reprogramming of neurons *in vitro*

Layal El Wazan, Daniel Urrutia-Cabrera, Raymond Ching-Bong Wong

**ORCID number:** Layal El Wazan (0000-0002-9869-2951); Daniel Urrutia-Cabrera (0000-0002-4610-5719); Raymond Ching-Bong Wong (0000-0002-8092-9455).

**Author contributions:** Wong RCB design the study; El Wazan L, Urrutia-Cabrera D, and Wong RCB wrote the paper.

**Supported by** funding from the Ophthalmic Research Institute of Australia, the University of Melbourne De Brettville Trust, the Kel and Rosie Day Foundation and the Centre for Eye Research Australia. The Centre for Eye Research Australia receives operational infrastructure support from the Victorian Government.

### Conflict-of-interest statement:

There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Layal El Wazan, Daniel Urrutia-Cabrera, Raymond Ching-Bong Wong,** Cellular Reprogramming Unit, Centre for Eye Research Australia, Melbourne 3004, Australia

**Layal El Wazan, Daniel Urrutia-Cabrera, Raymond Ching-Bong Wong,** Department of Surgery, University of Melbourne, Melbourne 3002, Australia

**Raymond Ching-Bong Wong,** Ophthalmology, Shenzhen Eye Hospital, Shenzhen 518040, Guangdong Province, China

**Corresponding author:** Raymond Ching-Bong Wong, BSc, PhD, Unit Head, Cellular Reprogramming Unit, Centre for Eye Research Australia, Level 6, 75 Commercial Road, Melbourne 3004, Australia. [wongcb@unimelb.edu.au](mailto:wongcb@unimelb.edu.au)  
**Telephone:** +61-39-9298054

### Abstract

Cell therapy offers great promises in replacing the neurons lost due to neurodegenerative diseases or injuries. However, a key challenge is the cellular source for transplantation which is often limited by donor availability. Direct reprogramming provides an exciting avenue to generate specialized neuron subtypes *in vitro*, which have the potential to be used for autologous transplantation, as well as generation of patient-specific disease models in the lab for drug discovery and testing gene therapy. Here we present a detailed review on transcription factors that promote direct reprogramming of specific neuronal subtypes with particular focus on glutamatergic, GABAergic, dopaminergic, sensory and retinal neurons. We will discuss the developmental role of master transcriptional regulators and specification factors for neuronal subtypes, and summarize their use in promoting direct reprogramming into different neuronal subtypes. Furthermore, we will discuss up-and-coming technologies that advance the cell reprogramming field, including the use of computational prediction of reprogramming factors, opportunity of cellular reprogramming using small chemicals and microRNA, as well as the exciting potential for applying direct reprogramming *in vivo* as a novel approach to promote neuro-regeneration within the body. Finally, we will highlight the clinical potential of direct reprogramming and discuss the hurdles that need to be overcome for clinical translation.

**Key words:** Cell reprogramming; Neuronal subtypes; Transcription factors; Direct reprogramming; Glutamatergic neurons; GABAergic neurons; Retinal neurons

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Manuscript source:** Invited manuscript

**Received:** February 22, 2019

**Peer-review started:** February 24, 2019

**First decision:** June 5, 2019

**Revised:** June 7, 2019

**Accepted:** June 27, 2019

**Article in press:** June 27, 2019

**Published online:** July 26, 2019

**P-Reviewer:** Andrukhov O, Hassan AI, Leanza G, Li SC

**S-Editor:** Yan JP

**L-Editor:** A

**E-Editor:** Ma YJ



**Core tip:** Direct reprogramming represents an innovative technology to generate neurons in the lab, which can be used for cell therapy, drug screening and disease modeling for neurodegenerative diseases. In this review we will discuss the current advance in identifying transcription factors to promote direct reprogramming of specialized neuronal subtypes, including glutamatergic, GABAergic, dopaminergic, sensory and retinal neurons. We will also discuss the hurdles that need to be overcome for clinical translation.

**Citation:** Wazan LE, Urrutia-Cabrera D, Wong RCB. Using transcription factors for direct reprogramming of neurons *in vitro*. *World J Stem Cells* 2019; 11(7): 431-444

**URL:** <https://www.wjgnet.com/1948-0210/full/v11/i7/431.htm>

**DOI:** <https://dx.doi.org/10.4252/wjsc.v11.i7.431>

## INTRODUCTION

The mammalian nervous system in adults has limited regenerative capacity, thus disease or trauma often cause permanent neuronal damages and have debilitating repercussions<sup>[1]</sup>. To facilitate regenerative medicine and repair damages in the nervous systems, we must develop robust methods to generate specialized subtypes of neurons efficiently in the laboratory. Cellular reprogramming could be the key to this issue, which utilizes transcription factors to convert one cell type into another. This was demonstrated by the early work of Takahashi and Yamanaka who were able to reprogram somatic cells into induced pluripotent stem (iPS) cells, using *Oct-3/4*, *Sox2*, *c-Myc*, and *Klf4*<sup>[2]</sup>. This seminal work established cellular reprogramming as a major game changer in generation of patient-specific cells *in vitro*<sup>[3]</sup> and enabled subsequent development of direct reprogramming, also known as trans-differentiation. A key characteristic of direct reprogramming is that this method bypasses the pluripotency stage and allows the conversion of one cell lineage directly to another, which represents a potentially faster method to generate cells compared to iPS cell generation and subsequent differentiation<sup>[4]</sup>.

Direct reprogramming allows the rapid generation of patient-derived neurons *in vitro*, providing a cellular source for transplantation, disease modelling, drug screening and gene therapy<sup>[5]</sup>. Previous studies have identified transcription factors that promote direct reprogramming of multiple starting cell types into specialized neuronal subtypes (Table 1, Figure 1). Here, we will summarize the role of proneural transcription factors in development and highlight their use in direct reprogramming, with particular focus on their use for specification of neuronal subtypes *in vitro*.

## MASTER REGULATORS OF THE NEURONAL LINEAGE

Proneural genes were first discovered in *Drosophila* by knockout studies to determine genes responsible for development of sensory bristles<sup>[6]</sup>. A lack of bristles in a scute mutant fly led to the discovery of many proneural genes essential to proper neural development of the fly<sup>[7]</sup>. Likewise, in the early developmental stages of humans, proneural factors promote neurogenesis and differentiation of progenitor cells to become specialised neurons<sup>[6]</sup>. For instances, basic helix loop helix (bHLH) genes are important regulators for the specification of neuronal cell fate and differentiation of neural cells in the central and peripheral nervous system<sup>[8]</sup>. Due to their importance in neural development, bHLH genes are often utilized in direct reprogramming to direct cells into the neuronal lineages<sup>[9]</sup>. bHLH genes can be categorized into two subtypes; specification and differentiation, both of which are important in the reprogramming of a neuronal subtype<sup>[8]</sup>.

*Mash1/Ascl1*, is a specification bHLH transcription factor found to be expressed in neural precursors of the developing embryo with a transient expression<sup>[8,10]</sup>. *Mash1/Ascl1* double knockout mice die within 24 h of birth and show major defects in the development of neuronal progenitors in olfactory epithelium, as well as lack of generation of sympathetic neurons. Hence, *Mash1/Ascl1* plays an important role in the development of neuronal progenitors<sup>[11]</sup>. In terms of direct reprogramming, *Ascl1* alone was shown to have the ability to reprogram mouse fibroblasts into functional induced neurons (iN). These iN exhibited the expression of mature neuronal markers, including Tuj1, NEUN, MAP2 and synapsin, after 21 d of induction. Notably, the iN

**Table 1 Summary of *in vitro* neuronal reprogramming studies discussed in this review with details of transcription factors used and neuronal characteristics**

Species	Cell of origin	Target cell	Transcription factor(s)	Neuronal characteristic	Year and ref.
Mouse	Embryonic fibroblasts	iN	<i>Ascl1</i>	Neuronal morphology Neuronal markers Functional electrophysiology	2014 <sup>[12]</sup>
Human	Fetal fibroblasts	iN	<i>ASCL1</i>	Neuronal morphology Neuronal markers	2014 <sup>[12]</sup>
Human	Fibroblasts	iN	<i>ASCL1</i> , <i>SOX2</i> and <i>NGN2</i>	Neuronal morphology Neuronal markers Neuronal gene expression profile Functional electrophysiology	2015 <sup>[14]</sup>
Mouse	Embryonic fibroblasts	iN	<i>Ascl1</i>	Simple neuronal morphology Neuronal markers	2010 <sup>[25]</sup>
Mouse	Embryonic fibroblasts	iN (mostly GABAergic and glutamatergic neurons)	<i>Brn2</i> , <i>Myt1l</i> , <i>Zic1</i> , <i>Olig2</i> , and <i>Ascl1</i>	Neuronal morphology Neuronal markers Functional electrophysiology Synaptic maturation	2010 <sup>[25]</sup>
Mouse	Embryonic fibroblasts	iN (mostly excitatory neurons)	<i>Brn2</i> , <i>Myt1l</i> , and <i>Ascl1</i>	Neuronal morphology Neuronal markers Functional electrophysiology Synaptic maturation	2010 <sup>[25]</sup>
Mouse	Adult tail tip fibroblasts	iN (mostly excitatory neurons)	<i>Brn2</i> , <i>Myt1l</i> , and <i>Ascl1</i>	Neuronal morphology Neuronal markers Functional electrophysiology Synaptic maturation	2010 <sup>[25]</sup>
Human	Fibroblasts	iN (mostly dopaminergic neurons)	<i>BRN2</i> , <i>MYT1</i> , <i>ASCL1</i> , <i>LMX1A</i> and <i>FOXA4</i>	Neuronal markers Functional electrophysiology	2011 <sup>[26]</sup>
Mouse	Embryonic fibroblasts	iN (mostly dopaminergic neurons)	<i>Mash1</i> , <i>Nurr1</i> and <i>Lmx1a</i>	Neuronal markers Neuronal gene expression profile Neuronal epigenetic reactivation Functional electrophysiology	2011 <sup>[33]</sup>
Human	Adult Fibroblasts	iN (mostly dopaminergic neurons)	<i>MASH1</i> , <i>NURR1</i> and <i>LMX1A</i>	Neuronal morphology Neuronal markers Neuronal gene expression profile Functional electrophysiology	2011 <sup>[33]</sup>
Human	Fibroblasts	iN (mostly dopaminergic neurons)	<i>ASCL1</i> , <i>NGN2</i> , <i>SOX2</i> , <i>NURR1</i> and <i>PITX3</i>	Neuronal morphology Neuronal markers Neuronal gene expression profile Functional electrophysiology	2012 <sup>[35]</sup>
Mouse	Embryonic fibroblasts	Induced sensory neurons	<i>Brn3a</i> and <i>Ngf</i> or <i>Ngf2</i>	Neuronal gene expression profile Functional electrophysiology Synaptic maturation	2015 <sup>[38]</sup>
Human	Adult fibroblasts	Induced sensory neurons	<i>BRN3A</i> and <i>NGN1</i> or <i>NGN2</i>	Neuronal morphology Neuronal markers Neuronal morphology Neuronal markers Functional electrophysiology	2015 <sup>[38]</sup>


Mouse	Embryonic fibroblasts	Induced nociceptors	<i>Ascl1, Myt1l, Ngn1, Isl2, and Klf7</i>	Neuronal morphology Neuronal markers Neuronal gene expression profile Functional electrophysiology Synaptic maturation	2014 <sup>[43]</sup>
Human	Fibroblasts	Induced nociceptors	<i>ASCL1, MYT1L, NGN1, ISL2 and KLF7</i>	Neuronal markers Functional electrophysiology	2014 <sup>[43]</sup>
Human	Iris cells	Photoreceptor- like cells	<i>Crx, Rx and Neurod1</i>	Neuronal morphology Neuronal markers Neuronal gene expression profile Functional light electrophysiology	2012 <sup>[47]</sup>
Human	Dermal fibroblasts	Photoreceptor- like cells	<i>CRX, RAX, NEUROD1 and OTX2</i>	Neuronal markers Neuronal gene expression profile Functional light electrophysiology	2014 <sup>[48]</sup>
Mouse	Müller glia	iN (mostly retinal glia-like neurons)	<i>Ngn2</i>	Neuronal morphology Neuronal markers Functional electrophysiology Neuronal gene expression profile	2018 <sup>[56]</sup>
Mouse	Müller glia	iN (mostly retinal neurons)	<i>Ascl1</i>	Neuronal morphology Neuronal markers Functional electrophysiology Neuronal gene expression profile	2018 <sup>[56]</sup>
Mouse	Cerebellum Astroglia	iN (mostly glutamatergic neurons)	<i>Ngn2</i>	Neuronal morphology Neuronal markers Synaptic maturation Functional electrophysiology	2017 <sup>[57]</sup>
Mouse	Cerebellum Astroglia	iN (mostly glutamatergic neurons)	<i>Ascl1</i>	Neuronal morphology Neuronal markers Synaptic maturation Functional electrophysiology	2017 <sup>[57]</sup>

iN: Induced neurons.

were predominantly excitatory as they expressed vesicular glutamatergic transporter 1 but not GABAergic transporter<sup>[12]</sup>. Furthermore, the use of *Ascl1* in a combinational approach with other transcription factors has shown to target reprogramming to specific neuronal subtype and improve maturation. This will be discussed further in the review under specific subtypes of neurons.

Another bHLH specification gene is neurogenin 2 (*NGN2*), which is found to have a similar expression pattern to *ASCL1* in undifferentiated neural crest cells during development. In neuronal reprogramming experiments *NGN2* and *ASCL1* can bind and interact when used in combination<sup>[13]</sup>, and increase the neuronal conversion efficiency by up to 13.4%<sup>[14]</sup>. However, other studies have shown that the expression of *NGN2* returns to basal level after neuronal conversions have occurred, suggesting that it is involved in the initial neuronal specification but doesn't have a long-term neuronal survival effect following reprogramming<sup>[15]</sup>.

Unlike the specification factors, differentiation factors have a role in the later maturation of neurons. The bHLH differentiation factor *NeuroD1* is absent in precursors and is found to increase expression by 50-fold once the neuron has reached terminal differentiation<sup>[16]</sup>. Its expression is required for both the maturation process as well as the survival of newly generated neurons<sup>[17]</sup>. *NeuroD1* is found to be upstream to *Ngn2*<sup>[18]</sup>. These factors show sequential expression which can be attributed to their loci placement. This pattern is commonly seen in transcription factors involved in different stages of the cell cycle. For instance, the specification factors are found upstream to the differentiation factors<sup>[19]</sup>. In addition, differentiation factors often play a major role in the neuronal reprogramming and maturation processes.



**Figure 1** Transcription factor combination used for *in vitro* direct reprogramming to specific neuron subtypes in mouse and human, including sensory neurons, GABAergic neurons, glutamatergic neurons, dopaminergic neurons, photoreceptors and retinal ganglion cells. A: Mouse; B: Human.

## TRANSCRIPTION FACTORS IN SPECIFICATION OF NEURONAL SUBTYPES

### Glutamatergic and GABAergic neurons

The *in vitro* generation of neuronal subtypes provides an invaluable resource for the study of many neuronal diseases. Figure 1 summarized the transcription factor combinations that were used for *in vitro* direct reprogramming into neuronal subtypes. One such promising effort is in the reprogramming of glutamatergic neurons. Glutamate is the major neurotransmitter of the central nervous system and

an imbalance in its production can lead to major neuronal defects<sup>[20,21]</sup>. Degradation of glutamatergic neurons is linked to disorders such as schizophrenia<sup>[22]</sup>. On the other hand, overexpression of glutamate can lead to excitotoxicity and glutamatergic cell death, which are associated with Alzheimer's disease and amyotrophic lateral sclerosis<sup>[23,24]</sup>.

As mentioned previously, *ASCL1* alone is capable of reprogramming fibroblasts into excitatory glutamatergic neurons. However, *ASCL1* is often used in a combinatorial transcription factor approach for direct reprogramming to generate neurons, such as the widely used BAM combination (*ASCL1*, *BRN2* and *MYT1L*) discovered by Vierbuchen *et al.*<sup>[25]</sup>. In this study, reprogramming using *ASCL1* alone resulted in generation of Tuj1-positive neurons. However, the morphological complexity, maturity and action potentials of the cells could be further improved by the addition of *BRN2* and *MYT1L*. BAM were able to reprogram fibroblasts into predominantly a mix of both glutamatergic and GABAergic neurons; while no other major neuronal subtypes were detected in significant numbers<sup>[26]</sup>. Unlike glutamate, gamma aminobutyric acid (GABA) is the major inhibitory neurotransmitter produced by GABAergic neurons<sup>[27]</sup>. A further study has discovered that BAM expression is only required in the initial stages of the reprogramming process and removing gene expression 3 days after transduction has no effect on the neuronal reprogramming process<sup>[26]</sup>.

The incorporation of *BRN2* and *MYT1L* into neuronal reprogramming is due to their importance in neural development. In the mouse hypothalamus, *BRN2* enhances neural differentiation during development and promotes activation of other events including the maturation and survival of paraventricular nuclei, as well as supraoptic nuclei<sup>[28,29]</sup>. *MYT1L* is a gene expressing a zinc finger protein which can be found in early differentiating neurons but is absent from glial cell populations, suggesting a role in early neuronal differentiation<sup>[30]</sup>. Although these factors are important for the reprogramming of neurons, neither *BRN2* or *MYT1L* alone is sufficient to induce neurons, as they require *ASCL1* to initiate the specification process<sup>[25]</sup>.

### Dopaminergic neurons

Dopaminergic (DA) neurons are the main source of dopamine production in the mammalian nervous system and its degeneration could lead to devastating neurological disorders, such as Parkinson's disease. Restoration of DA neurons in Parkinson's disease could provide a treatment for the disease as demonstrated in rat models<sup>[31]</sup>. In order to achieve this level of cell type specification, it is necessary to incorporate fate specification factors during the reprogramming process.

By incorporating the expression of DA specification factors *LMX1A* and *FOXA4* along with BAM factors, approximately 10% of the human iN reprogrammed from human embryonic fibroblasts were DA neurons. Interestingly, the same study found that *LMX1A* and *FOXA4* drove more human iN to a DA fate but did not increase the overall neuronal conversion rate<sup>[26]</sup>. The differentiation of DA neurons has been shown to be influenced by a positive feedback system in which *FOXA1* and *FOXA2* promote the expression of *LMX1A* and *LMX1B*, which subsequently leads to the development of mesodiencephalic DA neurons<sup>[32]</sup>.

There are also other studies that utilized alternative combination of factors with similar results. Caiazzo *et al.*<sup>[33]</sup> were able to induce DA neuron reprogramming using fibroblasts with a combination of *Ascl1*, *Nurr1* and *Lmx1a*. This 3-factor cocktail was able to induce approximately 85% iN that are positive for the DA marker, TH. In this regard, *Nurr1* is a DA specific receptor, essential for the formation and survival of DA neurons<sup>[34]</sup>. It is not activated by ligands but rather forms a heterodimer complex with retinoid X receptor (RXR), and together this complex is able to bind RXR ligands that produce signalling essential for the survival of DA neurons<sup>[34]</sup>.

A subsequent study identified another set of 5 transcription factors which successfully converted human fibroblasts into human-induced DA neurons: *ASCL1*, *NGN2*, *SOX2*, *NURR1* and *PITX3*. Importantly, *ASCL1*, *NGN2* and *SOX2* are required for this reprogramming process. On the other hand, exclusion of *NURR1* and *PITX3* did not have an effect in the early reprogramming process, rather these factors increased the dendrite network and facilitated maturation of DA neurons<sup>[35]</sup>.

### Sensory neurons

Diverse subtypes of sensory neurons are responsible for pain and itch perception. Mutations in sensory neuron-specific proteins result in development of a wide range of sensory disorders, such as Friedreich's ataxia<sup>[36]</sup>. Due to limited availability of human sensory neurons, research in this field is largely dependent on animal models, especially rodents. Therefore, many mechanisms involved in human pain and itch perception remain uncharacterized. Studies from human primary dorsal root ganglion (DRG) neurons have identified differences between human and mouse nociceptors in

function of individual channels, receptors and their response to chemical stimuli<sup>[37]</sup>. Hence, the development of protocols for the generation of bona-fide human sensory neurons in sufficient numbers is vital for accurate modeling of processes like pain and itch.

A previous study has demonstrated the feasibility of reprogramming fibroblasts into sensory neurons using a combination of *Brn3a* either with *Ngn1* or *Ngn2*<sup>[38]</sup>. The cells displayed pseudounipolar morphology, and selectively responded to chemical mimics of pain, temperature, and itch. Both combinations with *Ngn1* or *Ngn2* equally induced the differentiation into three functional classes of sensory neurons, expressing one of the tropomyosin receptor kinase TrkA, TrkB, or TrkC<sup>[38]</sup>. *Ngn1* and *Ngn2* are alternative neurogenic bHLH factors that are expressed within progenitors of the developing DRG<sup>[39]</sup>. Both factors promote cell cycle exit through the induction of *NeuroD1* and *NeuroD4*, and regulate two waves of neurogenesis<sup>[40–42]</sup>. *Ngn1* and *Ngn2* are co-expressed during much part of the early phase of DRG neurogenesis, and are both required for the generation of TrkB+ and TrkC+ sensory neurons. On the other hand, in the later phase *Ngn1* is exclusively expressed in neural precursors and is largely responsible for the development of TrkA+ class sensory neurons<sup>[39]</sup>. At the time of cell cycle exit, the sensory neurons express the “pan-sensory” factors *Brn3a* and *Isl1*, which terminate the expression of the bHLH neurogenic factors and initiate the expression of definitive sensory markers to complete neurogenesis<sup>[42]</sup>.

Similarly, functional nociceptor neurons can be generated through the transgenic expression of *Ascl1*, *Myt1l*, *Ngn1*, *Isl2*, and *Klf7* in mouse and human fibroblasts<sup>[43]</sup>. The resultant iN expressed functional receptors for the noxious compounds menthol (TrpM8), mustard oil (TrpA1) and capsaicin (TrpV1). They also displayed the nociceptor-specific TTX-resistant Nav1.8 sodium channel. Notably, these iN were able to replicate inflammatory and chemotherapy-induced sensitization, which form the basis of pathological pain. Furthermore, this reprogramming method was successful in the generation of patient-derived neurons from familial dysautonomia, thus representing a promising approach for disease modeling<sup>[43]</sup>. For the five factors employed, *Ascl1* and *Myt1l* are members of the three-factor combination for neuronal lineage reprogramming BAM<sup>[25]</sup>; *Klf7* is a factor involved in TrkA expression maintenance<sup>[44]</sup>; and *Isl2* was selected based on its expression profile in DRG<sup>[45]</sup>. The extent of *Isl2* contribution to the lineage reprogramming remained unknown and further studies are needed to clarify this.

### Retinal neurons

Retinal neurons are another promising target for therapeutic *in situ* reprogramming strategies. The retina is a highly organized structure bearing several major types of neurons, including rod and cone photoreceptors, bipolar, amacrine, horizontal and retinal ganglion cells (RGC)<sup>[46]</sup>. Rod and cone photoreceptors are responsible for detecting light stimuli and converting it to electrical signals that are later sent to the brain for visual perception. The loss of photoreceptors is a key hallmark of many blinding diseases and currently there are no effective treatments to cure blindness once photoreceptors are lost. Therefore, cellular reprogramming is a powerful technique for developing novel approaches for photoreceptor regeneration.

Akihiro Umezawa's group used a promising combination of factors (*CRX*, *RAX* and *NEUROD1*) to induce the conversion of both iris cells<sup>[47]</sup> and fibroblasts into photoreceptor-like cells<sup>[48]</sup>. These factors induced the expression of photoreceptor-related genes and the reprogrammed cells became positive for the rod marker rhodopsin and the cone marker blue-opsin. Notably, some of the reprogrammed cells were photoresponsive. Interestingly, the authors showed that although *OTX2* enhanced the upregulation of retinal genes, it was not essential for the reprogramming<sup>[48]</sup>. The same combination of factors was used to reprogram peripheral blood mononuclear cells<sup>[49]</sup>, which facilitate clinical applications of this reprogramming strategy as blood samples are easier to collect from patients than fibroblasts. The generated photoreceptor-like cells expressed blue and red/green opsin, and some of the cells were able to respond to light stimuli. However, the reprogrammed cells expressed low levels of rod marker rhodopsin and some photoreceptor-related genes were not detected, which indicated that additional factors might be required to produce mature and functional photoreceptors<sup>[49]</sup>.

In the developing retina, *OTX2* is expressed in progenitors and early precursors that become committed to a photoreceptor fate<sup>[50,51]</sup>. *NEUROD* and *CRX* are factors expressed in developing photoreceptors and their expression is maintained in photoreceptors of mature retina, therefore they are proposed to participate in cell fate specification, as well as in maturation and survival processes<sup>[41,51]</sup>. Additionally, *NEUROD* is known to promote neuron specification in retinal progenitors and regulates interneuron differentiation to direct the amacrine cells fate<sup>[41]</sup>. On the other hand, *CRX* is downstream of *OTX2* activity, it enhances the expression of

photoreceptor-specific genes and is important for terminal differentiation into rod and cone photoreceptors<sup>[51,52]</sup>. RAX is a factor expressed in retinal and hypothalamic progenitor cells and is a key transcription factor for eye development in vertebrates. In the developing retina, it is involved in retinal progenitor proliferation and photoreceptor fate specification<sup>[53-55]</sup>.

RGC are another interesting therapeutic target within the retina. These specialised retinal neurons form the optic nerve which convey the visual cues to the brain<sup>[46,51]</sup>. Degeneration of RGC is a major hallmark in glaucoma, a major blinding disease affecting the aging population<sup>[56]</sup>. Thus, *in vitro* generation of RGC offers an exciting avenue to develop regenerative therapy for this disease.

A study by Guimarães *et al*<sup>[56]</sup> demonstrated that RGC can be reprogrammed from postnatal Müller glia through the overexpression of *Ngn2*. The forced expression of *Ngn2* produced a pool of iN which express genes associated with photoreceptors, amacrine cells and RGCs. However, this was only possible with Müller glia from young mice, as P(21) Müller glia cells failed to reprogram into iN. They also showed that the presence of mitogenic factors like EGF or FGF2 during the expansion of Müller glia enhanced the efficiency of the reprogramming. This finding supports the theory that the starting cell types for reprogramming have a strong influence on the neuronal subtypes in the resultant iN. For instance, *ASCL1* or *NGN2* alone can reprogram astroglia from the cerebellum and neocortex into neuron subtypes in the brain<sup>[57]</sup>. On the other hand, these factors can drive reprogramming of Müller glia into iN subtypes with retinal neuronal identities<sup>[56,58]</sup>. Thus, careful consideration should be taken in choosing the starting cell type in reprogramming to generate specialized neuronal subtypes.

## NEW TECHNOLOGICAL ADVANCES IN CELLULAR REPROGRAMMING

Recent studies have demonstrated several exciting approaches to further develop the direct reprogramming processes. Here we will highlight and discuss the use of new technological advances in overcoming the hurdles of direct reprogramming as well as the potential of *in vivo* application of direct reprogramming to promote regeneration.

### Computational predictions of transcription factors

Most of the reprogramming studies mentioned above have taken a candidate elimination approach to identify the optimal set of transcription factor(s) required for direct reprogramming, which is a tedious and laborious screening process. Recent advances in computational biology provide an alternative approach to predict the required transcription factor for cellular reprogramming in a faster and more efficient manner. One early example is CellNet, a computational algorithm that analyzes, categorizes and predicts the function of transcription factors<sup>[59]</sup>. Subsequently, several other programs have been described to predict the transcription factors for cellular reprogramming, including Mogrify<sup>[60]</sup>, BART<sup>[61]</sup>, MAGICACT<sup>[62]</sup> and CellRouter<sup>[63]</sup>. Most of these programs work by comparing the quantitative amount of transcription factor in one cell type to another cell type to create a specificity score, which is used to create a ranking in which transcription factor are sorted and categorized depending on the cell type they are most prominent in<sup>[59,64]</sup>. Another exciting approach to predict transcription factors for cellular reprogramming is by creating computer models of cells. These programs, such as DeepNEU, can be used to create a simulation model of the cell using deep learning and provides a simulation of the events after the introduction of selected transcription factors<sup>[65]</sup>. Although these advanced algorithmic models are still in their infancy, further development will improve our understanding of the fundamental properties of cells and the molecular interplay of transcription factors that promote cellular reprogramming.

### In vivo application of direct reprogramming

The potential to apply direct reprogramming *in vivo* represents an exciting direction for regenerative medicine. Therapeutic approaches using *in vivo* reprogramming have the potential to re-purpose local cells into the cells lost following injury or disease, thus providing an alternative regenerative approach to transplantation<sup>[66]</sup>. This has already been demonstrated for many neuronal subtypes, including glutamatergic and GABAergic neurons<sup>[67]</sup>. It was shown that overexpression of *NeuroD1* is sufficient to convert astrocytes to glutamatergic neurons in rodents *in vivo*, as characterized by vGlut1 expression and glutamate-mediated synapses. Compared to astrocytes, interestingly the same study found that the NG2 glial cells have a larger reprogramming capacity into multiple neuronal subtypes, as the presence of both

glutamatergic and GABAergic neurons was detected after *NeuroD1* overexpression<sup>[67]</sup>.

There has also been an extensive effort to re-purpose local cells for retinal regeneration. Many studies target the Müller glia within the retina for *in vivo* reprogramming, which are cells responsible for maintaining the integrity and homeostasis of the retina<sup>[68]</sup>. Interestingly, the Müller glia exhibit some progenitor properties. In the teleost fish and chicken, upon retinal injury the Müller glia can dedifferentiate into multipotent progenitors and give rise to all retinal neural subtypes<sup>[69]</sup>. This remarkable trait makes Müller glia an excellent candidate for reprogramming studies.

In several elegant studies by Tom Reh's group, the author has demonstrated successful reprogramming of mouse Müller glia into a range of retinal neurons both *ex vivo* and *in vivo*, by the forced expression of the pro-neural factor *Ascl1*<sup>[58,70]</sup>. When *Ascl1* was overexpressed in retinal explants and in Müller glia dissociated cultures, the cells re-entered the mitotic cell cycle and expressed neural progenitor genes<sup>[58]</sup>. This reprogramming was accompanied with chromatin remodeling, acquisition of neural morphology and the ability to respond to neurotransmitters<sup>[58]</sup>. In addition to its role as a pioneer proneural factor for direct reprogramming and retinal development, *Ascl1* induction in response to injury is required for retinal regeneration in the fish<sup>[71-73]</sup>. Conversely, organisms with limited regenerative capacity in the retina do not upregulate *Ascl1* following retinal damage<sup>[58,74]</sup>. Subsequently, in a landmark study the same group extended the application of *Ascl1* to reprogram Müller glia into retinal neurons *in vivo* following retinal injury<sup>[70]</sup>. Marker analysis showed that the reprogrammed retinal neurons were able to functionally integrate with the existing retinal circuit. Interestingly, this reprogramming approach was less effective in adult mice compared to young mice<sup>[75]</sup>. The restrictive regenerative capacity of adult mice Müller glia is thought to be caused by reduced epigenetic accessibility of progenitor genes in the cell, as the addition of histone deacetylase trichostatin A is able to overcome this epigenetic hurdle in adult Müller glia<sup>[70]</sup>. In support of this, epigenetic profiling using ATAC-seq demonstrated that the treatment with trichostatin A favored the accessibility of genes associated with neural development and differentiation, such as *Otx2*<sup>[70]</sup>. In this case, *Otx2* is known to regulate genes associated with bipolar and amacrine cells. However, it should be noted that most of the reprogrammed retinal neurons are bipolar cells, suggesting that additional factors are required to induce photoreceptors *in vivo*.

A subsequent study from Bo Chen's group demonstrated that adult mice Müller glia can be reprogrammed to rod photoreceptors without the necessity of retinal injury<sup>[76]</sup>. In this study, the authors first stimulated Müller glia proliferation by forced expression of  $\beta$ -catenin, followed by overexpression of *Otx2*, *Crx* and *Nrl* after two weeks. This approach allowed successful generation of rod photoreceptors *in vivo* that functionally integrate into the retinal and visual cortex circuits. In a remarkable experiment, the authors were able to use this *in vivo* reprogramming approach to restore light response in a mouse model of photoreceptor degeneration. Collectively, these studies demonstrate the potential of *in vivo* reprogramming as a novel approach for neural regeneration.

### **Alternatives to transcription factor-mediated reprogramming**

Beside transcription factors, alternative direct reprogramming strategies using small chemicals and microRNAs are also two exciting research directions to improve the usability of the technology. For instance, chemical reprogramming using small chemicals has been shown to induce functional neurons without the need for transcription factor. A cocktail of 7 small molecules (Valproic acid, CHIR99021, Repsox, Forskolin, SP600125, GO6983 and Y-27632) was successful at reprogramming human fibroblasts into neurons with functional electrophysiology representative of glutamatergic and GABAergic cells<sup>[77]</sup>. Furthermore, the use of a combinational approach of small molecules together with transcription factors can improve direct reprogramming. In a study by Liu *et al*<sup>[15]</sup>, *NGN2* along with small molecules, forskolin and dorsomorphin, directly reprogrammed human fetal lung fibroblasts to cholinergic neurons with functional electrophysiology. In this regard, forskolin is a cAMP activator in the PKA signalling pathway and dorsomorphin acts as an inhibitor of the BMP signalling pathway, both of which are signaling pathways involved in neurogenesis.

Similarly, microRNAs have also been used in combinational approaches with transcription factors to induce neuronal reprogramming. microRNAs are known to play important roles in post transcriptional regulation, neural differentiation, morphological and phenotypic development<sup>[78-82]</sup>. In a study by Yoo *et al*<sup>[83]</sup>, miR-9/9\* and miR-124 were used in combination with *NEUROD1* to convert human fibroblasts into neurons, however these cells would not always demonstrate repetitive action potential, signifying immature neurons. In order to tackle this issue the same group

also introduced two other factors, *ASCL1* and *MYT1L*, and in turn were able to induce neurons with higher maturity which demonstrated repetitive action potentials. These studies highlighted alternative approaches to transcription factors that promote neuronal reprogramming.

## CLINICAL PERSPECTIVES OF *IN VITRO* NEURONAL REPROGRAMMING AND CHALLENGES FOR CLINICAL APPLICATION

Allogeneic transplantation represents a promising cell therapy approach to replace neurons lost by injury or neurodegenerative disease, such as Parkinson's disease<sup>[84]</sup>. However, there are two major challenges related to transplantation: (1) the shortage of donor tissue for transplantation; and (2) immuno-rejection issues of the grafted tissue. Development of stem cell and cell reprogramming technology to generate patient-specific cells *in vitro* would be critical to overcome these hurdles. Cell therapy strategy using pluripotent stem cells have been extensively highlighted previously<sup>[85-87]</sup>. In comparison, notably direct reprogramming bypasses the pluripotent stem cell state, thus this is potentially a faster and more cost-effective approach to generate neurons *in vitro*, with less tumorigenic risks compared to pluripotent stem cell strategy. Moreover, there is also the exciting opportunity to combine cellular reprogramming with gene therapy to correct disease-causing mutation(s) in the cells *in vitro*, prior to transplantation to patients to treat hereditary neurodegenerative diseases.

To facilitate clinical translation of direct reprogramming technology, it is critical to develop robust reprogramming protocol to generate target cells with high purity and efficiency. Optimization of transcription factors for direct reprogramming, as well as improved method for gene delivery would be key to improving the reprogramming efficiency. Flow cytometry or magnetic-activated cell sorting can be used to enrich the purity of the target cell type prior to transplantation. For clinical applications, cells derived by direct reprogramming should be produced under good manufacturing practices conditions. To ensure the quality of the reprogrammed cells, it is important that the derived cells are extensively characterized for marker expression and functional studies, and screened to ensure the derived cells have a normal karyotype. In the latter case, the use of non-integrative methods for direct reprogramming is desirable, such as Sendai viruses or episomal vectors.

## CONCLUSION

In summary, direct reprogramming allows the conversion of one somatic cell type directly to another cell type. The *in vitro* reprogramming of neurons provides an exciting avenue to generate patient-specific neurons for disease modelling, drug testing and cell therapy for neurodegenerative diseases. Transcription factors responsible for the specialization and differentiation of neuronal cells during development are commonly used for direct reprogramming to generate multiple neuronal subtypes. Future studies that optimize the precise combinations of transcription factors for neuronal reprogramming would improve the reprogramming efficiency, expand the neuronal subtypes that can be generated and facilitate the translation of cellular reprogramming to the clinics. Emerging computational algorithms and alternative reprogramming approaches will further improve the technique of direct reprogramming, and future application of direct reprogramming *in vivo* would provide a novel approach to promote regeneration in the nervous system.

## ACKNOWLEDGEMENTS

RW was supported by funding from the Ophthalmic Research Institute of Australia, the University of Melbourne De Brettville Trust, the Kel and Rosie Day Foundation and the Centre for Eye Research Australia. The Centre for Eye Research Australia receives operational infrastructure support from the Victorian Government.

## REFERENCES

- 1 Björklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. *Nat Neurosci*

- 2000; **3**: 537-544 [PMID: [10816308](#) DOI: [10.1038/75705](#)]
- 2 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: [16904174](#) DOI: [10.1016/j.cell.2006.07.024](#)]
- 3 **Hung SSC**, Khan S, Lo CY, Hewitt AW, Wong RCB. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases. *Pharmacol Ther* 2017; **177**: 32-43 [PMID: [28223228](#) DOI: [10.1016/j.pharmthera.2017.02.026](#)]
- 4 **Kelaini S**, Cochrane A, Margariti A. Direct reprogramming of adult cells: Avoiding the pluripotent state. *Stem Cells Cloning* 2014; **7**: 19-29 [PMID: [24627642](#) DOI: [10.2147/SCCAA.S38006](#)]
- 5 **Fang L**, El Wazan L, Tan C, Nguyen T, Hung SSC, Hewitt AW, Wong RCB. Potentials of Cellular Reprogramming as a Novel Strategy for Neuroregeneration. *Front Cell Neurosci* 2018; **12**: 460 [PMID: [30555303](#) DOI: [10.3389/fncel.2018.00460](#)]
- 6 **Bertrand N**, Castro DS, Guillemot F. Proneural genes and the specification of neural cell types. *Nat Rev Neurosci* 2002; **3**: 517-530 [PMID: [12094208](#) DOI: [10.1038/nrn874](#)]
- 7 **Ghyssen A**, Dambly-Chaudière C. From DNA to form: The achaete-scute complex. *Genes Dev* 1988; **2**: 495-501 [PMID: [3290049](#) DOI: [10.1101/gad.2.5.495](#)]
- 8 **Lee JE**. Basic helix-loop-helix genes in neural development. *Curr Opin Neurobiol* 1997; **7**: 13-20 [PMID: [9039799](#) DOI: [10.1016/S0959-4388\(97\)80115-8](#)]
- 9 **Vierbuchen T**, Wernig M. Molecular roadblocks for cellular reprogramming. *Mol Cell* 2012; **47**: 827-838 [PMID: [23020854](#) DOI: [10.1016/j.molcel.2012.09.008](#)]
- 10 **Lo LC**, Johnson JE, Wuenschell CW, Saito T, Anderson DJ. Mammalian achaete-scute homolog 1 is transiently expressed by spatially restricted subsets of early neuroepithelial and neural crest cells. *Genes Dev* 1991; **5**: 1524-1537 [PMID: [1909283](#) DOI: [10.1101/gad.5.9.1524](#)]
- 11 **Guillemot F**, Lo LC, Johnson JE, Auerbach A, Anderson DJ, Joyner AL. Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons. *Cell* 1993; **75**: 463-476 [PMID: [8221886](#) DOI: [10.1016/0092-8674\(93\)90381-Y](#)]
- 12 **Chanda S**, Ang CE, Davila J, Pak C, Mall M, Lee QY, Ahlenius H, Jung SW, Südhof TC, Wernig M. Generation of induced neuronal cells by the single reprogramming factor ASCL1. *Stem Cell Reports* 2014; **3**: 282-296 [PMID: [25254342](#) DOI: [10.1016/j.stemcr.2014.05.020](#)]
- 13 **Gradwohl G**, Fode C, Guillemot F. Restricted expression of a novel murine atonal-related bHLH protein in undifferentiated neural precursors. *Dev Biol* 1996; **180**: 227-241 [PMID: [8948587](#) DOI: [10.1006/dbio.1996.0297](#)]
- 14 **Zhao P**, Zhu T, Lu X, Zhu J, Li L. Neurogenin 2 enhances the generation of patient-specific induced neuronal cells. *Brain Res* 2015; **1615**: 51-60 [PMID: [25912433](#) DOI: [10.1016/j.brainres.2015.04.027](#)]
- 15 **Liu ML**, Zang T, Zou Y, Chang JC, Gibson JR, Huber KM, Zhang CL. Small molecules enable neurogenin 2 to efficiently convert human fibroblasts into cholinergic neurons. *Nat Commun* 2013; **4**: 2183 [PMID: [23873306](#) DOI: [10.1038/ncomms3183](#)]
- 16 **Boutin C**, Hardt O, de Chevigny A, Coré N, Goebbels S, Seidenfaden R, Bosio A, Cremer H. NeuroD1 induces terminal neuronal differentiation in olfactory neurogenesis. *Proc Natl Acad Sci USA* 2010; **107**: 1201-1206 [PMID: [20080708](#) DOI: [10.1073/pnas.0909015107](#)]
- 17 **Gao Z**, Ure K, Ables JL, Lagace DC, Nave KA, Goebbels S, Eisch AJ, Hsieh J. NeuroD1 is essential for the survival and maturation of adult-born neurons. *Nat Neurosci* 2009; **12**: 1090-1092 [PMID: [19701197](#) DOI: [10.1038/nn.2385](#)]
- 18 **Ma Q**, Kintner C, Anderson DJ. Identification of neurogenin, a vertebrate neuronal determination gene. *Cell* 1996; **87**: 43-52 [PMID: [8858147](#) DOI: [10.1016/S0092-8674\(00\)81321-5](#)]
- 19 **Weintraub H**. The MyoD family and myogenesis: Redundancy, networks, and thresholds. *Cell* 1993; **75**: 1241-1244 [PMID: [8269506](#) DOI: [10.1016/0092-8674\(93\)90610-3](#)]
- 20 **Fagg GE**, Foster AC. Amino acid neurotransmitters and their pathways in the mammalian central nervous system. *Neuroscience* 1983; **9**: 701-719 [PMID: [6137788](#) DOI: [10.1016/0306-4522\(83\)90263-4](#)]
- 21 **Fonnum F**. Glutamate: A neurotransmitter in mammalian brain. *J Neurochem* 1984; **42**: 1-11 [PMID: [6139418](#) DOI: [10.1111/j.1471-4159.1984.tb09689.x](#)]
- 22 **Kim JS**, Kornhuber HH, Schmid-Burgk W, Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. *Neurosci Lett* 1980; **20**: 379-382 [PMID: [6108541](#) DOI: [10.1016/0304-3940\(80\)90178-0](#)]
- 23 **Greenamyre JT**, Maragos WF, Albin RL, Penney JB, Young AB. Glutamate transmission and toxicity in Alzheimer's disease. *Prog Neuropsychopharmacol Biol Psychiatry* 1988; **12**: 421-430 [PMID: [2900537](#) DOI: [10.1016/0278-5846\(88\)90102-9](#)]
- 24 **Plaitakis A**. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: A hypothesis. *Ann Neurol* 1990; **28**: 3-8 [PMID: [1973889](#) DOI: [10.1002/ana.410280103](#)]
- 25 **Vierbuchen T**, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. *Nature* 2010; **463**: 1035-1041 [PMID: [20107439](#) DOI: [10.1038/nature08797](#)]
- 26 **Pfisterer U**, Kirkeby A, Torper O, Wood J, Nelander J, Dufour A, Björklund A, Lindvall O, Jakobsson J, Parmar M. Direct conversion of human fibroblasts to dopaminergic neurons. *Proc Natl Acad Sci USA* 2011; **108**: 10343-10348 [PMID: [21646515](#) DOI: [10.1073/pnas.1105135108](#)]
- 27 **Bettler B**, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABA(B) receptors. *Physiol Rev* 2004; **84**: 835-867 [PMID: [15269338](#) DOI: [10.1152/physrev.00036.2003](#)]
- 28 **Nakai S**, Kawano H, Yudate T, Nishi M, Kuno J, Nagata A, Jishage K, Hamada H, Fujii H, Kawamura K. The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. *Genes Dev* 1995; **9**: 3109-3121 [PMID: [8543155](#) DOI: [10.1101/gad.9.24.3109](#)]
- 29 **Schonemann MD**, Ryan AK, McEvelly RJ, O'Connell SM, Arias CA, Kalla KA, Li P, Sawchenko PE, Rosenfeld MG. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. *Genes Dev* 1995; **9**: 3122-3135 [PMID: [8543156](#) DOI: [10.1101/gad.9.24.3122](#)]
- 30 **Kim JG**, Armstrong RC, v Agoston D, Robinsky A, Wiese C, Nagle J, Hudson LD. Myelin transcription factor 1 (Myt1) of the oligodendrocyte lineage, along with a closely related CCHC zinc finger, is expressed in developing neurons in the mammalian central nervous system. *J Neurosci Res* 1997; **50**: 272-290 [PMID: [9373037](#) DOI: [10.1002/\(SICI\)1097-4547\(19971015\)50:2<272::AID-JNR16>3.0.CO;2-A](#)]
- 31 **Wernig M**, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O,

- Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. *Proc Natl Acad Sci U S A* 2008; **105**: 5856-5861 [PMID: 18391196 DOI: 10.1073/pnas.0801677105]
- 32 Lin W, Metzakopian E, Mavromatakis YE, Gao N, Balaskas N, Sasaki H, Briscoe J, Whitsett JA, Goulding M, Kaestner KH, Ang SL. Foxa1 and Foxa2 function both upstream of and cooperatively with Lmx1a and Lmx1b in a feedforward loop promoting mesodiencephalic dopaminergic neuron development. *Dev Biol* 2009; **333**: 386-396 [PMID: 19607821 DOI: 10.1016/j.ydbio.2009.07.006]
- 33 Caiazzo M, Dell'Anno MT, Dvoretzka E, Lazarevic D, Taverna S, Leo D, Sotnikova TD, Menegon A, Roncaglia P, Colciago G, Russo G, Carninci P, Pezzoli G, Gainetdinov RR, Gustincich S, Dityatev A, Broccoli V. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature* 2011; **476**: 224-227 [PMID: 21725324 DOI: 10.1038/nature10284]
- 34 Perlmann T, Wallén-Mackenzie A. Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells. *Cell Tissue Res* 2004; **318**: 45-52 [PMID: 15340833 DOI: 10.1007/s00441-004-0974-7]
- 35 Liu X, Li F, Stubblefield EA, Blanchard B, Richards TL, Larson GA, He Y, Huang Q, Tan AC, Zhang D, Benke TA, Sladek JR, Zahniser NR, Li CY. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. *Cell Res* 2012; **22**: 321-332 [PMID: 22105488 DOI: 10.1038/cr.2011.181]
- 36 Sghirlanzoni A, Pareyson D, Lauria G. Sensory neuron diseases. *Lancet Neurol* 2005; **4**: 349-361 [PMID: 15907739 DOI: 10.1016/S1474-4422(05)70096-X]
- 37 Davidson S, Copits BA, Zhang J, Page G, Ghetti A, Gereau RW. Human sensory neurons: Membrane properties and sensitization by inflammatory mediators. *Pain* 2014; **155**: 1861-1870 [PMID: 24973718 DOI: 10.1016/j.pain.2014.06.017]
- 38 Blanchard JW, Eade KT, Szűcs A, Lo Sardo V, Tsunemoto RK, Williams D, Sanna PP, Baldwin KK. Selective conversion of fibroblasts into peripheral sensory neurons. *Nat Neurosci* 2015; **18**: 25-35 [PMID: 25420069 DOI: 10.1038/nn.3887]
- 39 Ma Q, Fode C, Guillemot F, Anderson DJ. Neurogenin1 and neurogenin2 control two distinct waves of neurogenesis in developing dorsal root ganglia. *Genes Dev* 1999; **13**: 1717-1728 [PMID: 10398684 DOI: 10.1101/gad.13.13.1717]
- 40 Ma Q, Chen Z, del Barco Barrantes I, de la Pompa JL, Anderson DJ. neurogenin1 is essential for the determination of neuronal precursors for proximal cranial sensory ganglia. *Neuron* 1998; **20**: 469-482 [PMID: 9539122 DOI: 10.1016/S0896-6273(00)80988-5]
- 41 Morrow EM, Furukawa T, Lee JE, Cepko CL. NeuroD regulates multiple functions in the developing neural retina in rodent. *Development* 1999; **126**: 23-36 [PMID: 9834183 DOI: 10.1016/S0070-2153(08)60381-6]
- 42 Lanier J, Dykes IM, Nissen S, Eng SR, Turner EE. Brn3a regulates the transition from neurogenesis to terminal differentiation and represses non-neural gene expression in the trigeminal ganglion. *Dev Dyn* 2009; **238**: 3065-3079 [PMID: 19877281 DOI: 10.1002/dvdy.22145]
- 43 Wainger BJ, Buttermore ED, Oliveira JT, Mellin C, Lee S, Saber WA, Wang AJ, Ichida JK, Chiu IM, Barrett L, Huebner EA, Bilgin C, Tsujimoto N, Brenneis C, Kapur K, Rubin LL, Eggan K, Woolf CJ. Modeling pain *in vitro* using nociceptor neurons reprogrammed from fibroblasts. *Nat Neurosci* 2015; **18**: 17-24 [PMID: 25420066 DOI: 10.1038/nn.3886]
- 44 Lei L, Laub F, Lush M, Romero M, Zhou J, Luikart B, Klesse L, Ramirez F, Parada LF. The zinc finger transcription factor Klf7 is required for TrkA gene expression and development of nociceptive sensory neurons. *Genes Dev* 2005; **19**: 1354-1364 [PMID: 15937222 DOI: 10.1101/gad.1227705]
- 45 Allen Institute for Brain Science. Allen Spinal Cord Atlas, 2012 [cited 20 January 2019]. Available from: <https://alleninstitute.org/what-we-do/brain-science/>
- 46 Masland RH. The fundamental plan of the retina. *Nat Neurosci* 2001; **4**: 877-886 [PMID: 11528418 DOI: 10.1038/nn0901-877]
- 47 Seko Y, Azuma N, Kaneda M, Nakatani K, Miyagawa Y, Noshiro Y, Kurokawa R, Okano H, Umezawa A. Derivation of human differential photoreceptor-like cells from the iris by defined combinations of CRX, RX and NEUROD. *PLoS One* 2012; **7**: e35611 [PMID: 22558175 DOI: 10.1371/journal.pone.0035611]
- 48 Seko Y, Azuma N, Ishii T, Komuta Y, Miyamoto K, Miyagawa Y, Kaneda M, Umezawa A. Derivation of human differential photoreceptor cells from adult human dermal fibroblasts by defined combinations of CRX, RAX, OTX2 and NEUROD. *Genes Cells* 2014; **19**: 198-208 [PMID: 24456169 DOI: 10.1111/gtc.12127]
- 49 Komuta Y, Ishii T, Kaneda M, Ueda Y, Miyamoto K, Toyoda M, Umezawa A, Seko Y. *In vitro* transdifferentiation of human peripheral blood mononuclear cells to photoreceptor-like cells. *Biol Open* 2016; **5**: 709-719 [PMID: 27170256 DOI: 10.1242/bio.016477]
- 50 Nishida A, Furukawa A, Koike C, Tano Y, Aizawa S, Matsuo I, Furukawa T. Otx2 homeobox gene controls retinal photoreceptor cell fate and pineal gland development. *Nat Neurosci* 2003; **6**: 1255-1263 [PMID: 14625556 DOI: 10.1038/nn1155]
- 51 Swaroop A, Kim D, Forrest D. Transcriptional regulation of photoreceptor development and homeostasis in the mammalian retina. *Nat Rev Neurosci* 2010; **11**: 563-576 [PMID: 20648062 DOI: 10.1038/nrn2880]
- 52 Furukawa T, Morrow EM, Cepko CL. Crx, a novel otx-like homeobox gene, shows photoreceptor-specific expression and regulates photoreceptor differentiation. *Cell* 1997; **91**: 531-541 [PMID: 9390562 DOI: 10.1016/S0092-8674(00)80439-0]
- 53 Muranishi Y, Terada K, Furukawa T. An essential role for Rax in retina and neuroendocrine system development. *Dev Growth Differ* 2012; **54**: 341-348 [PMID: 22524605 DOI: 10.1111/j.1440-169X.2012.01337.x]
- 54 Furukawa T, Kozak CA, Cepko CL. rax, a novel paired-type homeobox gene, shows expression in the anterior neural fold and developing retina. *Proc Natl Acad Sci U S A* 1997; **94**: 3088-3093 [PMID: 9096350 DOI: 10.1073/pnas.94.7.3088]
- 55 Mathers PH, Grinberg A, Mahon KA, Jamrich M. The Rx homeobox gene is essential for vertebrate eye development. *Nature* 1997; **387**: 603-607 [PMID: 9177348 DOI: 10.1038/42475]
- 56 Guimarães RPM, Landeira BS, Coelho DM, Golbert DCF, Silveira MS, Linden R, de Melo Reis RA, Costa MR. Evidence of Müller Glia Conversion Into Retina Ganglion Cells Using Neurogenin2. *Front Cell Neurosci* 2018; **12**: 410 [PMID: 30483060 DOI: 10.3389/fncel.2018.00410]
- 57 Chouchane M, Melo de Farias AR, Moura DMS, Hilscher MM, Schroeder T, Leão RN, Costa MR. Lineage Reprogramming of Astroglial Cells from Different Origins into Distinct Neuronal Subtypes. *Stem Cell Reports* 2017; **9**: 162-176 [PMID: 28602612 DOI: 10.1016/j.stemcr.2017.05.009]
- 58 Pollak J, Wilken MS, Ueki Y, Cox KE, Sullivan JM, Taylor RJ, Levine EM, Reh TA. ASCL1 reprograms

- mouse Müller glia into neurogenic retinal progenitors. *Development* 2013; **140**: 2619-2631 [PMID: 23637330 DOI: 10.1242/dev.091355]
- 59 **Morris SA**, Cahan P, Li H, Zhao AM, San Roman AK, Shivdasani RA, Collins JJ, Daley GQ. Dissecting engineered cell types and enhancing cell fate conversion via CellNet. *Cell* 2014; **158**: 889-902 [PMID: 25126792 DOI: 10.1016/j.cell.2014.07.021]
- 60 **Rackham OJ**, Firas J, Fang H, Oates ME, Holmes ML, Knaupp AS; FANTOM Consortium, Suzuki H, Nefzger CM, Daub CO, Shin JW, Petretto E, Forrest AR, Hayashizaki Y, Polo JM, Gough J. A predictive computational framework for direct reprogramming between human cell types. *Nat Genet* 2016; **48**: 331-335 [PMID: 26780608 DOI: 10.1038/ng.3487]
- 61 **Wang Z**, Civelek M, Miller CL, Sheffield NC, Guertin MJ, Zang C. BART: A transcription factor prediction tool with query gene sets or epigenomic profiles. *Bioinformatics* 2018; **34**: 2867-2869 [PMID: 29608647 DOI: 10.1093/bioinformatics/bty194]
- 62 **Roopra A**. MAGICACT: A tool for predicting transcription factors and cofactors driving gene sets using ENCODE data. *BioRxiv* 2018, 492744. [DOI: 10.1101/492744]
- 63 **Lummertz da Rocha E**, Rowe RG, Lundin V, Malleshaiah M, Jha DK, Rambo CR, Li H, North TE, Collins JJ, Daley GQ. Reconstruction of complex single-cell trajectories using CellRouter. *Nat Commun* 2018; **9**: 892 [PMID: 29497036 DOI: 10.1038/s41467-018-03214-y]
- 64 **D'Alessio AC**, Fan ZP, Wert KJ, Baranov P, Cohen MA, Saini JS, Cohick E, Charniga C, Dadon D, Hannett NM, Young MJ, Temple S, Jaenisch R, Lee TI, Young RA. A Systematic Approach to Identify Candidate Transcription Factors that Control Cell Identity. *Stem Cell Reports* 2015; **5**: 763-775 [PMID: 26603904 DOI: 10.1016/j.stemcr.2015.09.016]
- 65 **Danter WR**. DeepNEU: cellular reprogramming comes of age - a machine learning platform with application to rare diseases research. *Orphanet J Rare Dis* 2019; **14**: 13 [PMID: 30630505 DOI: 10.1186/s13023-018-0983-3]
- 66 **Nguyen T**, Wong RC. Neuroregeneration using *in vivo* cellular reprogramming. *Neural Regen Res* 2017; **12**: 1073-1074 [PMID: 28852386 DOI: 10.4103/1673-5374.211182]
- 67 **Guo Z**, Zhang L, Wu Z, Chen Y, Wang F, Chen G. *In vivo* direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. *Cell Stem Cell* 2014; **14**: 188-202 [PMID: 24360883 DOI: 10.1016/j.stem.2013.12.001]
- 68 **Wang J**, O'Sullivan ML, Mukherjee D, Puñal VM, Farsi S, Kay JN. Anatomy and spatial organization of Müller glia in mouse retina. *J Comp Neurol* 2017; **525**: 1759-1777 [PMID: 27997986 DOI: 10.1002/cne.24153]
- 69 **Lenkowski JR**, Raymond PA. Müller glia: Stem cells for generation and regeneration of retinal neurons in teleost fish. *Prog Retin Eye Res* 2014; **40**: 94-123 [PMID: 24412518 DOI: 10.1016/j.preteyeres.2013.12.007]
- 70 **Jorstad NL**, Wilken MS, Grimes WN, Wohl SG, VandenBosch LS, Yoshimatsu T, Wong RO, Rieke F, Reh TA. Stimulation of functional neuronal regeneration from Müller glia in adult mice. *Nature* 2017; **548**: 103-107 [PMID: 28746305 DOI: 10.1038/nature23283]
- 71 **Fausett BV**, Gumerson JD, Goldman D. The proneural basic helix-loop-helix gene *ascl1a* is required for retina regeneration. *J Neurosci* 2008; **28**: 1109-1117 [PMID: 18234889 DOI: 10.1523/JNEUROSCI.4853-07.2008]
- 72 **Ramachandran R**, Zhao XF, Goldman D. *Insm1a*-mediated gene repression is essential for the formation and differentiation of Müller glia-derived progenitors in the injured retina. *Nat Cell Biol* 2012; **14**: 1013-1023 [PMID: 23000964 DOI: 10.1038/ncb2586]
- 73 **Wan J**, Ramachandran R, Goldman D. HB-EGF is necessary and sufficient for Müller glia dedifferentiation and retina regeneration. *Dev Cell* 2012; **22**: 334-347 [PMID: 22340497 DOI: 10.1016/j.devcel.2011.11.020]
- 74 **Karl MO**, Hayes S, Nelson BR, Tan K, Buckingham B, Reh TA. Stimulation of neural regeneration in the mouse retina. *Proc Natl Acad Sci U S A* 2008; **105**: 19508-19513 [PMID: 19033471 DOI: 10.1073/pnas.0807453105]
- 75 **Ueki Y**, Wilken MS, Cox KE, Chipman L, Jorstad N, Sternhagen K, Simic M, Ullom K, Nakafuku M, Reh TA. Transgenic expression of the proneural transcription factor *Ascl1* in Müller glia stimulates retinal regeneration in young mice. *Proc Natl Acad Sci U S A* 2015; **112**: 13717-13722 [PMID: 26483457 DOI: 10.1073/pnas.1510595112]
- 76 **Yao K**, Qiu S, Wang YV, Park SJH, Mohs EJ, Mehta B, Liu X, Chang B, Zenisek D, Crair MC, Demb JB, Chen B. Restoration of vision after de novo genesis of rod photoreceptors in mammalian retinas. *Nature* 2018; **560**: 484-488 [PMID: 30111842 DOI: 10.1038/s41586-018-0425-3]
- 77 **Hu W**, Qiu B, Guan W, Wang Q, Wang M, Li W, Gao L, Shen L, Huang Y, Xie G, Zhao H, Jin Y, Tang B, Yu Y, Zhao J, Pei G. Direct Conversion of Normal and Alzheimer's Disease Human Fibroblasts into Neuronal Cells by Small Molecules. *Cell Stem Cell* 2015; **17**: 204-212 [PMID: 26253202 DOI: 10.1016/j.stem.2015.07.006]
- 78 **Ebert MS**, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. *Cell* 2012; **149**: 515-524 [PMID: 22541426 DOI: 10.1016/j.cell.2012.04.005]
- 79 **De Pietri Tonelli D**, Pulvers JN, Haffner C, Murchison EP, Hannon GJ, Huttner WB. miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex. *Development* 2008; **135**: 3911-3921 [PMID: 18997113 DOI: 10.1242/dev.025080]
- 80 **Kawase-Koga Y**, Low R, Otaegi G, Pollock A, Deng H, Eisenhaber F, Maurer-Stroh S, Sun T. RNAase-III enzyme Dicer maintains signaling pathways for differentiation and survival in mouse cortical neural stem cells. *J Cell Sci* 2010; **123**: 586-594 [PMID: 20103535 DOI: 10.1242/jcs.059659]
- 81 **Kawase-Koga Y**, Otaegi G, Sun T. Different timings of Dicer deletion affect neurogenesis and gliogenesis in the developing mouse central nervous system. *Dev Dyn* 2009; **238**: 2800-2812 [PMID: 19806666 DOI: 10.1002/dvdy.22109]
- 82 **Babiarz JE**, Hsu R, Melton C, Thomas M, Ullian EM, Blelloch R. A role for noncanonical microRNAs in the mammalian brain revealed by phenotypic differences in *Dicer8* versus *Dicer1* knockouts and small RNA sequencing. *RNA* 2011; **17**: 1489-1501 [PMID: 21712401 DOI: 10.1261/rna.2442211]
- 83 **Yoo AS**, Sun AX, Li L, Shcheglovitov A, Portmann T, Li Y, Lee-Messer C, Dolmetsch RE, Tsien RW, Crabtree GR. MicroRNA-mediated conversion of human fibroblasts to neurons. *Nature* 2011; **476**: 228-231 [PMID: 21753754 DOI: 10.1038/nature10323]
- 84 **Lindvall O**, Brundin P, Widner H, Rehnström S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD. Grafts of fetal dopamine neurons survive and improve motor function in

- Parkinson's disease. *Science* 1990; **247**: 574-577 [PMID: 2105529 DOI: 10.1126/science.2105529]
- 85 **Thies RS**, Murry CE. The advancement of human pluripotent stem cell-derived therapies into the clinic. *Development* 2015; **142**: 3077-3084 [PMID: 26395136 DOI: 10.1242/dev.126482]
- 86 **Trounson A**, DeWitt ND. Pluripotent stem cells progressing to the clinic. *Nat Rev Mol Cell Biol* 2016; **17**: 194-200 [PMID: 26908143 DOI: 10.1038/nrm.2016.10]
- 87 **Martin U**. Therapeutic Application of Pluripotent Stem Cells: Challenges and Risks. *Front Med (Lausanne)* 2017; **4**: 229 [PMID: 29312943 DOI: 10.3389/fmed.2017.00229]



Published By Baishideng Publishing Group Inc  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

